Anti-Human TGF beta 2 Recombinant Antibody (Lerdelimumab) (CAT#: TAB-100)

Figure 1 Real-time RT-PCR assays validated a subset of CRTC1-MAML2 fusion-regulated genes identified from microarray analysis.

Real-time RT-PCR analyses showed that knockdown of both CRTC1-MAML2 fusion and MAML2 in H3118 MEC cells led to reduced transcripts levels of a known target AREG and a subset of novel fusion target genes, including LINC00473, DMBT1, STC1, PDE4B, RUNX1, PTGS1, TGFB2, ODC1, and CDK6.

Chen, J., Li, J. L., Chen, Z., Griffin, J. D., & Wu, L. (2015). Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells. BMC cancer, 15(1), 803.

Figure 1 Anti-TGF beta 2 Antibody (TAB-100) in SDS-PAGE

SDS-PAGE analysis of TAB-100 in non-reduced (lane 1) and β-mercaptoethanol-reduced (lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates as 130-180 kDa.

Figure 2 Anti-TGF beta 2 Antibody (TAB-100) in HPLC

The purity of TAB-100 was greater than 95% as determined by SEC-HPLC.

Column: 3 µm, 7.8x300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.3
Detection: UV280 nm
Injection: 10 µl